2022 World Conference on Lung Cancer (ePosters)-EP16.03-006. Genetic Characteristics of EGFR Concurrent Variants with RB1 and TP53 in NCSLC Patients

Pdf Summary

In this study, the genetic characteristics of concurrent variants in EGFR, RB1, and TP53 genes in Chinese non-small cell lung cancer (NSCLC) patients were investigated. The study aimed to understand the impact of these variants on the effectiveness of EGFR tyrosine kinase inhibitors (TKIs), which are commonly used in the treatment of NSCLC patients with EGFR sensitive mutations.<br /><br />A total of 10,182 NSCLC patients were included in the study, and it was found that 48.9% of them had EGFR-sensitive alterations. Among these patients, 6.9% had RB1 variants, and 48.5% had TP53 variants. The most frequent alterations in the EGFR-sensitive cases were found in TP53 (48.5%), RBM10 (9.7%), CDKN2A (9.3%), TERT (8.5%), and PIK3CA (7.3%).<br /><br />The study also revealed that 3.4% of patients with EGFR sensitive mutations had RB1 alterations, and 23.7% had TP53 alterations. Additionally, nearly 2.9% of patients showed triple changes in EGFR, RB1, and TP53. It was suggested that these concurrent variants may affect the effectiveness of EGFR-TKIs.<br /><br />Furthermore, the relationship between PD-L1 status and tumor mutation burden (TMB) was evaluated. It was found that there was a significant difference in TMB between PD-L1 positive and negative cases, with PD-L1 positive cases having a higher median TMB.<br /><br />The study concludes that concurrent variants in EGFR, RB1, and TP53 genes are common in NSCLC patients with EGFR sensitive mutations, and these variants may impact the efficacy of EGFR-TKIs. The findings highlight the importance of using next-generation sequencing (NGS) in the precise treatment of NSCLC patients with EGFR sensitive mutations.<br /><br />Overall, this study provides valuable insights into the genetic characteristics of NSCLC patients and their potential implications for treatment decisions.

Asset Subtitle

Hui Chen

Meta Tag

Speaker Hui Chen

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

genetic characteristics

concurrent variants

EGFR

RB1

TP53

NSCLC

EGFR-sensitive alterations

PD-L1 status

tumor mutation burden

next-generation sequencing